Menthol Enhances an Antiproliferative Activity of 1α,25-Dihydroxyvitamin D₃ in LNCaP Cells

Eun-Jung Park, Su-Hwa Kim, Byung-Joo Kim, Sung-Young Kim, Insuk So, and Ju-Hong Jeon*

Department of Physiology, Seoul National University College of Medicine, Seoul 110-799, Korea

Received 24 July, 2008; Accepted 8 September, 2008

Summary 1α,25-dihydroxyvitamin D₃ [1α,25(OH)₂D₃], the most active form of vitamin D₃, and its analogues have therapeutic benefits for prostate cancer treatment. However, the development of hypercalcemia is an obstacle to clinical applications of 1α,25(OH)₂D₃ for cancer therapy. In this study, we provide evidence that menthol, a key component of peppermint oil, increases an anti-proliferation activity of 1α,25(OH)₂D₃ in LNCaP prostate cancer cells. We found that menthol per se does not exhibit antiproliferative activity, but it is able to enhance 1α,25(OH)₂D₃-mediated growth inhibition in LNCaP cells. Fluorometric assays using Fura-2 showed that 1α,25(OH)₂D₃ does not induce acute Ca²⁺ response, whereas menthol evokes an increase in [Ca²⁺]ᵢ, which suggests that cross-talks of menthol-induced Ca²⁺ signaling with 1α,25(OH)₂D₃-mediated growth inhibition pathways. In addition, Western blot analysis revealed that 1α,25(OH)₂D₃ and menthol cooperatively modulate the expression of bcl-2 and p21 which provides the insight into the molecular mechanisms underlying the enhanced 1α,25(OH)₂D₃-mediated growth inhibition by menthol. Thus, our findings suggest that menthol may be a useful natural compound to enhance therapeutic effects of 1α,25(OH)₂D₃.

Key Words: 1α,25(OH)₂D₃, menthol, anti-proliferation, prostate cancer

Introduction

Prostate cancer, the most commonly diagnosed non-cutaneous cancer, is one of the main causes of cancer death in men [1]. It is a heterogeneous disease with a highly varied clinical course ranging from asymptomatic to fatal malignancy [2]. Initial growth of prostate cancer depends on androgen, and thereby responds to androgen-deprivation therapy [2]. However, almost all of the patients eventually become refractory to androgen-deprivation therapy and die of recurrent androgen-independent cancer for which no effective therapy is available [2].

Many epidemiologic studies have identified the low level of circulating 25-hydroxyvitamin D₃, the most commonly used index of vitamin D status, as a significant risk factor for prostate cancer [3]. Recent clinical trials have proven that 1α, 25-dihydroxyvitamin D₃ [1α,25(OH)₂D₃] and its analogues have therapeutic benefits for cancer treatment [4, 5]. 1α,25(OH)₂D₃ exerts antitumor effects through the transcriptional regulation of the genes involved in cell cycle, differentiation, and apoptosis [6]. 1α,25(OH)₂D₃-mediated transcription is achieved by its binding to vitamin D receptor (VDR), of which knockout mice are vulnerable to chemical carcinogenesis in several tissues [5, 7]. In addition, 1α,25(OH)₂D₃ can elicit transcription-independent non-genomic responses, such as acute Ca²⁺ influx and its resultant signaling cascade activation, which can in turn elevate VDR activity [4, 8]. Thus, an understanding of vitamin D signaling pathways can help to devise novel approaches to prostate cancer therapy. However, administration of 1α,25(OH)₂D₃ is limited by hypercalcemic toxicity [4, 5]. Thus, the development of safe and effective strategies improving anticancer efficacy and reducing toxicity is required for successful use of 1α,25(OH)₂D₃.

Menthol, 2-isopropyl-5-methylcyclohexanol, has been
widely used as an active ingredient of food, cosmetic, and pharmaceutical products [9]. It is a key component of peppermint oil that has a variety of biological activities, including antitumor activity and chemopreventive potential [10]. Because menthol was found to increase [Ca$^{2+}$]i in prostate cancer cell lines [11, 12], we questioned whether menthol can enhance an antiproliferative activity of 1α,25(OH)2D3. In this study, we demonstrated that menthol per se little affects cell growth but enhances an antiproliferative activity of 1α,25(OH)2D3 in LNCaP prostate cancer cells. Our findings suggest that a combination of 1α,25(OH)2D3 with menthol could be a promising therapeutic strategy for prostate cancer.

Materials and Methods

Cell culture

LNCaP cells were supplied by Korean Cell Line Bank (KCLB, Seoul, Korea) and maintained in RPMI media plus 10% FBS. All cell culture agents used were obtained from Invitrogen. 1α,25(OH)2D3 and (-)-menthol (Sigma, St. Louis, MO) in ethanol were added to the culture medium as the indicated concentrations or times.

Cell growth assay

LNCaP cells were grown in 12-well or 24-well culture plates (Nunc, Roskilde, Denmark). MTT assay was used to assess cell growth according to the manufacturer’s instruction (Sigma). Assays were quantitated by measuring the absorbance at 570 nm on a microplate spectrophotometer (Asys Hitech, Cambridge, UK).

Intracellular Ca$^{2+}$ measurement

The detached cells were incubated with 5 μM Fura-2-AM (Molecular probes, Eugene, OR) in normal Tyrode’s solution for 20 min at 37°C. After washing twice, the cells were resuspended with normal Tyrode’s solution consisting of 10 mM HEPES, 145 mM NaCl, 3.6 mM KCl, 1 mM MgCl2, 1.3 mM CaCl2, and 5 mM glucose. Fluorescence emission at 510 nm was measured with excitation at 340/380 nm in a stirred quartz-microcuvette (1 ml volume at 37°C) of fluorescence spectrophotometer (Photoron Technology Instrument, Birmingham, NJ). Maximum and minimum fluorescence values at 380 nm (Fmax and Fmin) were calibrated with 0.2% Triton X-100 and 10 mM EGTA, respectively. The [Ca$^{2+}$]i was calculated from the equation, [Ca$^{2+}$]i = Kd × β × (R – Rmin) / (Rmax – R) where Kd is the dissociation constant for Fura-2 (224 nM), β is Fmin/Fmax, and R is F340/F380.

Western blot analysis

The total proteins were prepared by incubation with RIPA buffer containing protease inhibitor (Roche, Indianapolis, IN) and phosphatase inhibitor cocktail (Calbiochem, Darmstadt, Germany). The proteins were resolved in 8–12% SDS-PAGE and analyzed with antibodies specific for caspase-3 (Cell Signaling, Danvers, MA), PARP (Cell Signaling), Bel-2 (SantaCruz, Santa Cruz, CA), p21 (SantaCruz), and p27 (SantaCruz). Antibody to GAPDH (SantaCruz) was used as a loading control.

Statistical analysis

Data was expressed as mean ± SD. Statistical significance was assessed by paired or unpaired t test using GraphPad Prism. Differences resulting in p values <0.05 were considered to be statistically significant.

Results

Menthol increases antiproliferative activity of 1α,25(OH)2D3

To assess the antiproliferative activity of menthol, we performed MTT assays using LNCaP cells. Cell growth was gradually decreased depending on menthol concentration (Fig. 1A). At high menthol concentrations above 1.6 mM, the cells began to detach from the culture dish. Although only a few cells were detached immediately after treatment with menthol at 0.8 mM, overall cell growth was not significantly reduced (Fig. 1A). The antiproliferative or cytotoxic effect of menthol was evident only in the presence of the supramillimolar concentration ranges, which indicates that menthol per se has little antitumor activity. We then investigated whether menthol can increase an antiproliferative activity of 1α,25(OH)2D3 in LNCaP cells. The combination of 1α,25(OH)2D3 with menthol above 0.8 mM suppressed significantly cell growth, compared to 1α,25(OH)2D3 alone (Fig. 1B). Dose-response relationship study confirmed that menthol markedly enhances an antiproliferative activity of 1α,25(OH)2D3 (Fig. 1C). These results were further corroborated by quantititating cell growth over time (Fig. 1D). While 1α,25(OH)2D3 alone attenuated cell growth, 1α,25(OH)2D3 combined with menthol almost completely inhibited the growth. Under the conditions, the considerable cell death, as examined by LDH release assay, did not occur and little apparent morphological changes were observed (data not shown).

Menthol, but not 1α,25(OH)2D3, evokes an increase in [Ca$^{2+}$]i

1α,25(OH)2D3 is known to increase [Ca$^{2+}$]i through its nongenomic action [4, 8]. Also, menthol can increase [Ca$^{2+}$]i, via transmembrane influx or store release pathways [12, 13]. We thus examined whether 1α,25(OH)2D3 and/or menthol can induce the change of [Ca$^{2+}$]i in LNCaP cells. Fluorescence-based ratiometric assays with Fura-2 showed that 1α,25(OH)2D3 does not increase [Ca$^{2+}$]i in our assay conditions (Fig. 2A), which indicates that no nongenomic Ca$^{2+}$ response occurs in LNCaP cells. By contrast, menthol

J. Clin. Biochem. Nutr.
Effect of Menthol and Vitamin D on LNCaP Cell Growth

Fig. 1. Antiproliferation effect of 1α,25(OH)2D3 and menthol in LNCaP cells. (A–C) Dose-response effect. The cells were cultured with menthol alone (A), 1α,25(OH)2D3 at 10⁻⁴ mM plus menthol at the indicated concentrations (B), or menthol at 0.8 mM plus 1α,25(OH)2D3 at the indicated concentrations (C) for 72 h prior to MTT assays. (D) Time-dependent effect. Cell growth is expressed as a relative value to that of the untreated cells or that of cells harvested at zero time. NC, negative control (ethanol as a vehicle); M, menthol; V, 1α,25(OH)2D3; M+V, menthol plus 1α,25(OH)2D3. The figures show mean ± SD (n = 3–6). *p<0.05, **p<0.01, ***p<0.005.

Fig. 2. Intracellular Ca²⁺ change in LNCaP cells exposed to 1α,25(OH)2D3 and menthol. The [Ca²⁺]i was measured using Fura-2 as described in Materials and Methods (A) The effect of 1α,25(OH)2D3 on [Ca²⁺]i. (B) The effect of menthol alone (0.8 mM) or 1α,25(OH)2D3 (10⁻⁴ mM) plus menthol (0.8 mM) on [Ca²⁺]i. Data shown are a representative result of at least three independent experiments. Arrows indicates the point of treatments with 1α,25(OH)2D3 and/or menthol.
The expression of apoptosis- or cell cycle-related genes in LNCaP cells exposed to 10⁻⁸ mM 1α,25(OH)₂D₃ and 0.8 mM menthol. Western blot analyses of proteins following treatment with 1α,25(OH)₂D₃ and menthol for 72 h. Data shown are a representative result of at least four independent experiments. GAPDH was used as a loading control.

**Combination of 1α,25(OH)₂D₃ with menthol cooperatively modulates bcl-2 and p21 expression**

To get a clue to the molecular mechanisms underlying the enhanced antiproliferation effect of the combination of 1α,25(OH)₂D₃ with menthol, we performed Western blot analyses with LNCaP cells. Neither caspase-3 nor PARP, a caspase-3 substrate, was cleaved in the experimental conditions used (Fig. 3A) which indicates that 1α,25(OH)₂D₃ plus menthol does not induce caspase-3-dependent apoptosis. We then examined the expression levels of an anti-apoptotic gene bcl-2 and cell cycle inhibitors p21 and p27. The expression of bcl-2 was markedly reduced by the combined treatment of 1α,25(OH)₂D₃ with menthol, which may permit the cells to be vulnerable to apoptotic stimuli. The expression level of bcl-2 appeared to be unaffected by either alone (Fig. 3B). However, of five independent experiments, we once observed the reduced expression of bcl-2 by 1α,25(OH)₂D₃ alone but not by menthol alone. The expression of p21 was reduced by treatment with either alone, but the reduction of p21 was more remarkable when 1α,25(OH)₂D₃ was combined with menthol (Fig. 3B). The expression of p27 was not affected by 1α,25(OH)₂D₃ or menthol, either alone or in combination (Fig. 3B).

**Discussion**

In the present study we described the advantageous effect of 1α,25(OH)₂D₃ combined with menthol. We showed that menthol *per se* exhibits little antiproliferative or pro-apoptotic activity (Fig. 1A), but it is able to enhance an antiproliferative activity of 1α,25(OH)₂D₃ in LNCaP cells (Fig. 1B-D). These results suggest that menthol is helpful to improve the anti-cancer efficacy and to reduce the hypercalcemic toxicity of 1α,25(OH)₂D₃. In addition, our findings suggest that menthol is a valuable probe to identify the novel pathways that determine 1α,25(OH)₂D₃ reactivity.

1α,25(OH)₂D₃ is known to up-regulate the expression of transient receptor potential vanilloid 6 (TRPV6), a Ca²⁺-selective cation channel [14], TRPV6 mediates transcellular Ca²⁺ transport at the apical membrane of the duodenal and renal epithelial cells [15]. TRPV6 ablation mice showed aberrant Ca²⁺ handling, such as reduced intestinal Ca²⁺ absorption and increased urinary Ca²⁺ excretion [15]. These results suggest that TRPV6 is an crucial transcriptional target of 1α,25(OH)₂D₃ for maintaining body Ca²⁺ homeostasis. In addition, 1α,25(OH)₂D₃ mediates Ca²⁺ influx via membrane-type VDR and unidentified Ca²⁺ channel activation that is transcription-independent processes, which is well exemplified in intestinal epithelial cells [4]. It has of interest been shown that 1α,25(OH)₂D₃ increases the expression of TRPV6 in LNCaP cells. [14, 16]. Thus, it is likely that 1α,25(OH)₂D₃ mediates Ca²⁺ transport via the genomic action involving the transcriptional induction of TRPV6. However, it has been undetermined whether 1α,25(OH)₂D₃-mediated TRPV6 induction is a crucial mechanism for 1α,25(OH)₂D₃-induced growth inhibition. Little has been known as to whether acute Ca²⁺ responses of 1α,25(OH)₂D₃ occurs in prostate cancer cells like those in intestinal epithelial cells. In this study, we did not find that 1α,25(OH)₂D₃ elicits acute Ca²⁺ response in LNCaP cells (Fig. 2A). When [Ca²⁺] was measured for 30 min, we still did not see acute [Ca²⁺] increase (Data not shown). These results suggest that membrane-type VDR or Ca²⁺ transport proteins are impaired in LNCaP cells, permitting tumor cells to be resistant to 1α,25(OH)₂D₃-induced growth inhibition, which may be a survival strategy of tumor cells. In addition, it is likely that the acute Ca²⁺ responsiveness to 1α,25(OH)₂D₃ is crucial for maximizing its therapeutic effect.

Menthol binds and activates transient receptor potential melastatin 8 (TRPM8), a Ca²⁺-permeable nonselective cation channel, to increase [Ca²⁺] [12]. Compared to 1α,25(OH)₂D₃ (Fig. 2A), menthol evoked an increase in [Ca²⁺] in LNCaP cells (Fig. 2B). TRPM8 activation can be sufficiently achieved by menthol at submillimolar concentrations [12, 13]. By contrast, our results showed that growth inhibition or cell death occurs only in the presence of supramillimolar concentrations of menthol (Fig. 1A), which indicates that antiproliferative or cytotoxic activity of menthol is independent of TRPM8 in LNCaP cells. However, it is still unsolved question whether TRPM8 is a key mediator in the enhanced cellular responses to 1α,25(OH)₂D₃ by...
menthol. Currently, answering this question is not easy due to technical limitations, such as lack of TRPM8-specific inhibitors. In addition, siRNA-mediated TRPM8 knockdown may induce cell death; despite the underlying molecular mechanisms are unclear [11]. Furthermore, a recent study showed that menthol increases [Ca\textsuperscript{2+}] through TRPM8-independent pathways [13]. Interestingly, both TRPV6 and TRPM8 are up-regulated in the early-stage of prostate cancer [17], which suggests that the simultaneous or sequential activation of two different Ca\textsuperscript{2+} pathways contributes to growth inhibition of prostate cancer. However, a causal relationship between these channels and tumorigenesis or tumor progression is uncertain. Moreover, little is known about the regulatory mechanisms of both channels concerning pathophysiologically relevant conditions, such as proliferative inflammatory atrophy [18].

The effect of 1α,25(OH)\textsubscript{2}D\textsubscript{3} on the expression level of bcl-2 or p21 is controversial, probably due to the cell-types and experimental conditions used [4, 19]. In this study, we found that the expression level of bcl-2 was reduced only by the combination of 1α,25(OH)\textsubscript{2}D\textsubscript{3} with menthol (Fig. 3B). In addition, we showed that combined treatment more remarkably reduces the expression level of p21 than treatment with either 1α,25(OH)\textsubscript{2}D\textsubscript{3} or menthol alone. Previous preclinical studies showed that the reduction of p21 sensitizes cancer cells to anticancer drugs [19]. Thus, these results raise the possibility that 1α,25(OH)\textsubscript{2}D\textsubscript{3} plus menthol can sensitize the cancer cells to chemotherapeutic agents. Unfortunately, here we did provide the detailed molecular mechanisms by which menthol enhances 1α,25(OH)\textsubscript{2}D\textsubscript{3} activity. Our preliminary results from reporter assays showed that menthol does not activate 1α,25(OH)\textsubscript{2}D\textsubscript{3}-mediated transcription (data not shown), which suggests that the effect of menthol is unrelated to the modulation of VDR activity. In several cancers, 24-hydroxylase, a 1α,25(OH)\textsubscript{2}D\textsubscript{3} catabolic enzyme, is known to be up-regulated to inactivate 1α,25(OH)\textsubscript{2}D\textsubscript{3} rapidly [4], which may be a tumor escaping mechanism conferring vitamin D resistance. Thus, the effect of menthol on 1α,25(OH)\textsubscript{2}D\textsubscript{3} metabolic enzymes appears to be a challengeable issue to be determined.

Acknowledgement

This study was supported by a grant of the Korea Health 21R&D project, Ministry of Health, Welfare and Family Affairs, Republic of Korea (A060058) and by Seoul National University Hospital Research Fund (09-2006-005-0). P.E.J., K.S.H., and K.B.J were supported by graduate program of BK21 project from Ministry of Ministry of Education, Science and Technology.

References

[1] Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M.J.: Cancer statistics 2006. CA Cancer J. Clin., 56, 106–130, 2006.

[2] Feldman, B.J. and Feldman, D.: The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1, 34–45, 2001.

[3] Holick, M.F.: Vitamin D deficiency. N. Engl. J. Med., 357, 266–281, 2007.

[4] Deeb, K.K., Trump, D.L., and Johnson, C.S.: Vitamin D signalling pathways in cancer, potential for anticancer therapeutics. Nat. Rev. Cancer, 7, 684–700, 2007.

[5] Trump, D.L., Hershberger, P.A., Bernardi, R.J., Ahmed, S., Muindi, J., Fakih, M., Yu, W.D., and Johnson, C.S.: Antitumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol., 89–90, 519–526, 2004.

[6] Wang, T.T., Tavares-Mendoza, L.E., Lapereiere, D., Libby, E., MacLeod, N.B., Nagai, Y., Bourdeau, V., Konstorum, A., Lallemant, B., Zhang, R., Mader, S., and White, J.H.: Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol., 19, 2685–2695, 2005.

[7] Welsh, J.: Vitamin D and breast cancer: insights from animal models. Am. J. Clin. Nutr., 80, 1721S–1724S, 2004.

[8] Norman, A.W.: Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology, 147, 5542–5548, 2006.

[9] Patel, T., Ishiiju, Y., and Yosipovitch, G.: Menthol: a refreshing look at this ancient compound. J. Am. Acad. Dermatol., 57, 873–878, 2007.

[10] McKay, D.L. and Blumberg, J.B.: A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.). Phytother. Res., 20, 619–633, 2006.

[11] Zhang, L. and Barratt, G.J.: Evidence that TRPM8 is an androgen-dependent Ca\textsuperscript{2+} channel required for the survival of prostate cancer cells. Cancer Res., 64, 8365–8373, 2004.

[12] Voets, T., Owssianik, G., and Nilius, B.: TRPM8. Handb. Exp. Pharmacol., 179, 329–344, 2007.

[13] Mahieu, F., Owssianik, G., Verbert, L., Janssens, A., De Smedt, H., Nilius, B., and Voets, T.: TRPM8-independent menthol-induced Ca\textsuperscript{2+} release from endoplasmic reticulum and Golgi. J. Biol. Chem., 282, 3325–3336, 2007.

[14] Meyer, M.B., Watanuki, M., Kim, S., Shevde, N.K., and Pike, J.W.: The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells. Mol. Endocrinol., 20, 1447–1461, 2006.

[15] Bianco, S.D., Peng, J.B., Takanaga, H., Suzuki, Y., Crescenzii, A., Kos, C.H., Zhuang, L., Freeman, M.R., Gouveia, C.H., Wu, J., Luo, H., Mauro, T., Brown, E.M., and Hediger, M.A.: Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene. J. Bone Miner. Res., 22, 274–285, 2007.

[16] Lehen’kyi, V., Flourakis, M., Skryma, R., and Prevarskaya, N.: TRPV6 channel controls prostate cancer cell proliferation.
via Ca(2+)/NFAT-dependent pathways. *Oncogene*, 26, 7380–7385, 2007.

[17] Monteith, G.R., McAndrew, D., Faddy, H.M., and Roberts-Thomson, S.J.: Calcium and cancer: targeting Ca2+ transport. *Nat. Rev. Cancer*, 7, 519–530, 2007.

[18] De Marzo, A.M., Platz, E.A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C.G., Nakai, Y., Isaacs, W.B., and Nelson, W.G.: Inflammation in prostate carcinogenesis. *Nat. Rev. Cancer*, 7, 256–269, 2007.

[19] Hershberger, P.A., Yu, W.D., Modzelewski, R.A., Rueger, R.M., Johnson, C.S., and Trump, D.L.: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. *Clin. Cancer Res.*, 7, 1043–1051, 2001.